Flufenamic Acid
規格
530-78-9CAS番号
208-494-1EC番号
2-[3-(trifluoromethyl)anilino]benzoic acidIUPAC名
C14H10F3NO2化学式
281.23 g/mol分子量
flufenamic acid; 530-78-9; Arlef; Fluphenamic acid; Achless; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; N-(3-Trifluoromethylphenyl)anthranilic acid; Acido flufenamico; Flufenaminsaeure; Meralen; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; Acide flufenamique; 2-[3-(Trifluoromethyl)anilino]benzoic acid; CI 440; NSC-82699; Acidum flufenamicum; 2-[[3-(Trifluoromethyl)phenyl]amino]benzoic acid; CN-27,554; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; INF-1837; DTXSID7023063; Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-; Benzoic acid, 2-((3-(trifluoromethyl)phenyl)amino)-; 60GCX7Y6BH; N-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid; NSC-219007; CHEBI:42638; CI-440; CN-27554; DTXCID303063; Acid, Flufenamic; 2-(3-(trifluoromethyl)anilino)benzoic acid; flufenamic acid aluminium; RefChem:388982; M01AG03; 208-494-1; Fullsafe; Nichisedan; Tecramine; Paraflu; Parlef; Flufacid; Lanceat; Plostene; Parlif; Surika; Reumajust A; Ristogen; Sastridex; Ansatin; Fluore-200; ANT-1; TVX 916; INF 1837; MFCD00002422; C.I. 440; NSC 219007; 2-(3-Trifluoromethylanilino)benzoic Acid; N-[3-(Trifluoromethyl)phenyl]anthranilic acid; 2-((3-Trifluromethyl)phenyl)aminobenzoic acid; 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID; N-(m-Trifluoromethylphenyl)-2-aminobenzoic acid; CHEMBL23588; MLS000028563; Saal-F; NCGC00016490-06; CAS-530-78-9; SMR000059027; N-(3-Trifluoromethylphenyl)-anthranilic acid; WLN: QVR BMR CXFFF; FFA; F0909-0007; Flufenamicacid; N-(.alpha.,.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid; Flufenaminsaeure [German]; Acido flufenamico [Italian]; FLF; CCRIS 5266; 2-[(3-Trifluromethyl)phenyl]aminobenzoic acid; N-[(3-Trifluoromethyl)phenyl]anthranilic acid; Acide flufenamique [INN-French]; Acido flufenamico [INN-Spanish]; Acidum flufenamicum [INN-Latin]; N-((m-Trifluoromethyl)phenyl)-2-aminobenzoic acid; N-[(m-Trifluoromethyl)phenyl]-2-aminobenzoic acid; N-[m-(Trifluoromethyl)phenyl]-2-aminobenzoic acid; SR-01000000241; EINECS 208-494-1; Anthranilic acid,.alpha.,.alpha.-trifluoro-m-tolyl)-; N-(.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid; UNII-60GCX7Y6BH; Flufenamic acid [USAN:INN:BAN:JAN]; BRN 1996069; flufenamic-acid; Prestwick_220; Arlef (TN); Spectrum_001257; 1bm7; Opera_ID_578; Prestwick0_000203; Prestwick1_000203; Prestwick2_000203; Prestwick3_000203; Spectrum2_000789; Spectrum3_001273; Spectrum4_000102; Spectrum5_000686; Etofenamate EP Impurity A; Epitope ID:613429; EC 208-494-1; Flufenamic acid (Standard); CBiol_001756; SCHEMBL17497; BSPBio_000185; BSPBio_001319; BSPBio_002866; CBDivE_012649; FLUFENAMIC ACID [MI]; KBioGR_000039; KBioGR_000424; KBioGR_002267; KBioSS_000039; KBioSS_001737; KBioSS_002268; 3-14-00-00905 (Beilstein Handbook Reference); MLS001148610; DivK1c_000581; FLUFENAMIC ACID [INN]; FLUFENAMIC ACID [JAN]; SPECTRUM1501015; SPBio_000898; SPBio_002106; FLUFENAMIC ACID [USAN]; BPBio1_000205; GTPL2447; orb1310228; FLUFENAMIC ACID [MART.]; SCHEMBL29356958; BCBcMAP01_000039; BDBM17636; HMS501N03; HY-B1221R; KBio1_000581; KBio2_000039; KBio2_001737; KBio2_002267; KBio2_002607; KBio2_004305; KBio2_004835; KBio2_005175; KBio2_006873; KBio2_007403; KBio3_000077; KBio3_000078; KBio3_002366; KBio3_002747; Anthranilic acid, N-(alpha,alpha,alpha-trifluoro-m-tolyl)-; FLUFENAMIC ACID [WHO-DD]; MSK8002; cMAP_000004; NINDS_000581; Bio1_000042; Bio1_000531; Bio1_001020; Bio2_000039; Bio2_000519; Flufenamic acid (JAN/USAN/INN); GLXC-27023; HMS1361B21; HMS1568J07; HMS1791B21; HMS1921B21; HMS1989B21; HMS2089E07; HMS2092B09; HMS2095J07; HMS2232G24; HMS3371F01; HMS3402B21; HMS3652F06; HMS3712J07; HMS3885P15; HMS5082J22; Pharmakon1600-01501015; SMSSF-0062312; HY-B1221; NSC82699; Tox21_110452; Tox21_302111; CCG-40167; EBC-04210; MSK8002-100A; NSC219007; NSC757823; s4268; SBB001140; STK985630; AKOS000265536; MSK8002-1000A; Tox21_110452_1; CS-4811; DB02266; FF23323; KS-1143; NSC-757823; Etofenamate EP Impurity A (Free Base); IDI1_000581; IDI1_033789; NCGC00016490-01; NCGC00016490-02; NCGC00016490-03; NCGC00016490-04; NCGC00016490-05; NCGC00016490-07; NCGC00016490-08; NCGC00016490-09; NCGC00016490-10; NCGC00016490-12; NCGC00023200-03; NCGC00023200-04; NCGC00023200-05; NCGC00023200-06; NCGC00023200-07; NCGC00255175-01; CN-27544; ST026563; SY014664; SBI-0051633.P002; DB-052254; 2-[3-(trifluoromethyl)anilino]-benzoic acid; AB00052198; ETOFENAMATE IMPURITY A [EP IMPURITY]; F4483; n-(a,a,a-trifluoro-m-tolyl)anthranilic acid; NS00000475; SW196528-3; UNM000001246003; 2-[3-(Trifluoromethyl)anilino]benzoic acid #; EN300-16858; o-[m-(trifluoromethyl)phenylamino]benzoic acid; 2-[(3-Trifluoromethylphenyl)amino]benzoic Acid; D01581; D97458; AB00052198-14; AB00052198_15; F358173; Q416341; 3'-Trifluoromethyldiphenylamine-2-carbox ylic acid; Flufenamic acid Solution in Acetonitrile, 100ug/mL; SR-01000000241-2; SR-01000000241-3; BRD-K44067360-001-06-3; BRD-K44067360-001-16-2; BRD-K44067360-001-29-5; BRD-K44067360-001-30-3; Flufenamic acid Solution in Acetonitrile, 1000ug/mL; Z56797275; Flufenamic acid, analytical standard, for drug analysis; Anthranilic acid, N-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-; FFA, Flufenamic acid, 3-[(2-Carboxyphenyl)amino]benzotrifluoride, 2-Carboxy-3'-(trifluoromethyl)diphenylamine別名
Flufenamic Acidを含む製品
Flufenamic Acidを販売する企業
NS
NINGBO SMART PHARMACEUTICAL CO.,LTDChinaDL
DILIGENT LIFE CARE PVT LTDIndiaEL
ENDOC LIFECARE PVT. LTD.IndiaSR
Suzhou Ryway Biotech Co., LtdChinaSR
Suzhou Ryway BiotechChina
(주
(주)마더스제약Republic of KoreaAC
AFINE CHEMICALS LIMITEDSB
Shaanxi Baoxin Pharmaceutical Co.,Ltd.China